LIANY
LianBio
Price Chart
Latest Quote
$0.16
+0.05 (+44.14%)
Current Price
| Previous Close | $0.11 |
| Open | $0.16 |
| Day High | $0.16 |
| Day Low | $0.16 |
| Volume | 100 |
Stock Information
| Shares Outstanding | 109.13M |
| Total Debt | $2.84M |
| Cash Equivalents | $252.22M |
| Net Income | $-87.98M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $17.46M |
| EPS (TTM) | $-2.00 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-198.33M |
| Income | $-87.98M |
| Book/sh | $1.89 |
| Cash/sh | $2.31 |
| Employees | 163 |
Financial Ratios
| Quick Ratio | 9.91 |
| Current Ratio | 10.06 |
| Debt/Eq | 1.20 |
Returns & Margins
| ROA | -21.67% |
| ROE | -32.42% |
Ownership
| Institutional Ownership | 7.46% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.44 |
| P/B | 0.08 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.13 |
| SMA50 | $0.13 |
| SMA200 | $0.10 |
| RSI | 49.10 |
| ATR | 0.0299 |
| Shares Float | 107.65M |
| Short Float | 0.83% |
| Short Ratio | 0.40 |
| Volatility | 0.04 |
| Rel Volume | 0.18 |
Performance History
| Week | +44.14% |
| Month | +45.45% |
| Quarter | -9.60% |
| 6 Months | +49.53% |
| YTD | +68.42% |
| Year | -2458.18% |
| 3 Years | -10297.88% |
| 10 Years | -1953.48% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $0.16 | 300 |
| 2026-06-23 | $0.11 | 700 |
| 2026-06-22 | $0.13 | 1,600 |
| 2026-06-18 | $0.11 | 600 |
| 2026-06-17 | $0.11 | 200 |
| 2026-06-16 | $0.11 | 0 |
| 2026-06-15 | $0.11 | 600 |
| 2026-06-12 | $0.16 | 300 |
| 2026-06-11 | $0.11 | 300 |
| 2026-06-10 | $0.11 | 3,000 |
| 2026-06-09 | $0.16 | 0 |
| 2026-06-08 | $0.16 | 500 |
| 2026-06-05 | $0.16 | 1,700 |
| 2026-06-04 | $0.14 | 5,300 |
| 2026-06-03 | $0.17 | 11,400 |
| 2026-06-02 | $0.11 | 2,500 |
| 2026-06-01 | $0.11 | 2,600 |
| 2026-05-29 | $0.14 | 2,100 |
| 2026-05-28 | $0.11 | 400 |
| 2026-05-27 | $0.11 | 0 |
| 2026-05-26 | $0.11 | 100 |
About LianBio
LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 gene amplification; and BBP-398 for solid tumors. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
đ° Latest News
No news articles available at the moment. Check back later for updates on LIANY.
Period:
Loading...
Income Statement (Annual)
| Metric | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $0 | $0 |
| Operating Revenue | $0 | $0 |
| Expenses | ||
| Total Expenses | $125,353,000 | $195,570,000 |
| Other Income Expense | $10,409,000 | $-455,000 |
| Other Non Operating Income Expenses | $10,409,000 | $-455,000 |
| Net Non Operating Interest Income Expense | $4,321,000 | $243,000 |
| Total Other Finance Cost | $-4,321,000 | $-243,000 |
| Operating Expense | $125,353,000 | $195,570,000 |
| General And Administrative Expense | $65,598,000 | $36,878,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-110,290,000 | $-196,300,000 |
| Net Interest Income | $4,321,000 | $243,000 |
| Normalized Income | $-110,290,000 | $-196,300,000 |
| Net Income From Continuing And Discontinued Operation | $-110,290,000 | $-196,300,000 |
| Total Operating Income As Reported | $-125,353,000 | $-195,570,000 |
| Net Income Common Stockholders | $-110,290,000 | $-196,300,000 |
| Net Income | $-110,290,000 | $-196,300,000 |
| Net Income Including Noncontrolling Interests | $-110,290,000 | $-196,300,000 |
| Net Income Continuous Operations | $-110,290,000 | $-196,300,000 |
| Pretax Income | $-110,623,000 | $-195,782,000 |
| Operating Income | $-125,353,000 | $-195,570,000 |
| Per Share | ||
| Diluted EPS | $-1.02 | $-5.71 |
| Basic EPS | $-1.02 | $-5.71 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-124,347,000 | $-195,045,000 |
| Reconciled Depreciation | $1,006,000 | $525,000 |
| EBITDA (Bullshit earnings) | $-124,347,000 | $-195,045,000 |
| EBIT | $-125,353,000 | $-195,570,000 |
| Diluted Average Shares | $107,923,296 | $34,394,622 |
| Basic Average Shares | $107,923,296 | $34,394,622 |
| Diluted NI Availto Com Stockholders | $-110,290,000 | $-196,300,000 |
| Tax Provision | $-333,000 | $518,000 |
| Research And Development | $59,755,000 | $158,692,000 |
| Selling General And Administration | $65,598,000 | $36,878,000 |
| Other Gand A | $65,598,000 | $36,878,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $259,873,000 | $353,562,000 |
| Total Assets | $319,960,000 | $426,343,000 |
| Total Non Current Assets | $7,187,000 | $26,696,000 |
| Other Non Current Assets | $93,000 | $20,051,000 |
| Current Assets | $312,773,000 | $399,647,000 |
| Prepaid Assets | $6,000,000 | $9,178,000 |
| Receivables | $4,410,000 | $7,220,000 |
| Other Receivables | $1,770,000 | $6,044,000 |
| Taxes Receivable | $2,640,000 | $1,176,000 |
| Cash Cash Equivalents And Short Term Investments | $302,363,000 | $383,249,000 |
| Cash And Cash Equivalents | $79,221,000 | $228,182,000 |
| Cash Equivalents | $11,242,000 | $155,995,000 |
| Cash Financial | $67,979,000 | $72,187,000 |
| Current Deferred Assets | - | $3,000 |
| Debt | ||
| Total Debt | $4,339,000 | $4,834,000 |
| Long Term Debt And Capital Lease Obligation | $2,488,000 | $3,709,000 |
| Current Debt And Capital Lease Obligation | $1,851,000 | $1,125,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $26,313,000 | $39,007,000 |
| Total Non Current Liabilities Net Minority Interest | $2,698,000 | $23,915,000 |
| Other Non Current Liabilities | $210,000 | $20,206,000 |
| Current Liabilities | $23,615,000 | $15,092,000 |
| Other Current Liabilities | $485,000 | $760,000 |
| Payables And Accrued Expenses | $13,446,000 | $10,898,000 |
| Payables | $1,453,000 | $3,231,000 |
| Accounts Payable | $1,453,000 | $3,231,000 |
| Equity | ||
| Common Stock Equity | $259,873,000 | $353,562,000 |
| Total Equity Gross Minority Interest | $293,647,000 | $387,336,000 |
| Stockholders Equity | $259,873,000 | $353,562,000 |
| Gains Losses Not Affecting Retained Earnings | $-2,080,000 | $526,000 |
| Other Equity Adjustments | $-2,080,000 | $526,000 |
| Retained Earnings | $-470,525,000 | $-360,235,000 |
| Preferred Securities Outside Stock Equity | - | $0 |
| Other | ||
| Ordinary Shares Number | $107,043,924 | $107,275,458 |
| Share Issued | $107,043,924 | $107,275,458 |
| Tangible Book Value | $259,873,000 | $353,562,000 |
| Invested Capital | $259,873,000 | $353,562,000 |
| Working Capital | $289,158,000 | $384,555,000 |
| Capital Lease Obligations | $4,339,000 | $4,834,000 |
| Total Capitalization | $259,873,000 | $353,562,000 |
| Minority Interest | $33,774,000 | $33,774,000 |
| Additional Paid In Capital | $732,476,000 | $713,269,000 |
| Capital Stock | $2,000 | $2,000 |
| Common Stock | $2,000 | $2,000 |
| Long Term Capital Lease Obligation | $2,488,000 | $3,709,000 |
| Current Capital Lease Obligation | $1,851,000 | $1,125,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,833,000 | $2,309,000 |
| Current Accrued Expenses | $11,993,000 | $7,667,000 |
| Net PPE | $7,094,000 | $6,645,000 |
| Accumulated Depreciation | $-1,547,000 | $-606,000 |
| Gross PPE | $8,641,000 | $7,251,000 |
| Leases | $3,372,000 | $807,000 |
| Construction In Progress | $67,000 | $1,145,000 |
| Other Properties | $3,978,000 | $4,763,000 |
| Machinery Furniture Equipment | $1,224,000 | $536,000 |
| Properties | $0 | $0 |
| Other Short Term Investments | $223,142,000 | $155,067,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2022-12-31 | 2021-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-101,030,000 | $-164,900,000 |
| Operating Activities | ||
| Operating Cash Flow | $-99,185,000 | $-163,953,000 |
| Cash Flow From Continuing Operating Activities | $-99,185,000 | $-163,953,000 |
| Operating Gains Losses | $127,000 | $87,000 |
| Investing Activities | ||
| Capital Expenditure | $-1,845,000 | $-947,000 |
| Investing Cash Flow | $-69,201,000 | $-155,937,000 |
| Cash Flow From Continuing Investing Activities | $-69,201,000 | $-155,937,000 |
| Financing Activities | ||
| Issuance Of Capital Stock | $0 | $314,083,000 |
| Financing Cash Flow | $1,710,000 | $313,273,000 |
| Cash Flow From Continuing Financing Activities | $1,710,000 | $313,273,000 |
| Net Preferred Stock Issuance | $0 | $3,000,000 |
| Preferred Stock Issuance | $0 | $3,000,000 |
| Net Common Stock Issuance | $0 | $311,083,000 |
| Common Stock Issuance | $0 | $311,083,000 |
| Net Other Financing Charges | - | $-6,356,000 |
| Other | ||
| Income Tax Paid Supplemental Data | $375,000 | $0 |
| End Cash Position | $79,294,000 | $248,182,000 |
| Beginning Cash Position | $248,182,000 | $254,350,000 |
| Effect Of Exchange Rate Changes | $-2,212,000 | $449,000 |
| Changes In Cash | $-166,676,000 | $-6,617,000 |
| Proceeds From Stock Option Exercised | $1,710,000 | $5,546,000 |
| Net Investment Purchase And Sale | $-67,356,000 | $-154,990,000 |
| Sale Of Investment | $235,780,000 | $0 |
| Purchase Of Investment | $-303,136,000 | $-154,990,000 |
| Net PPE Purchase And Sale | $-1,845,000 | $-947,000 |
| Purchase Of PPE | $-1,845,000 | $-947,000 |
| Change In Working Capital | $7,995,000 | $13,785,000 |
| Change In Other Current Liabilities | $-97,000 | $732,000 |
| Change In Other Current Assets | $27,000 | $-40,000 |
| Change In Payables And Accrued Expense | $8,137,000 | $7,053,000 |
| Change In Accrued Expense | $9,842,000 | $8,761,000 |
| Change In Payable | $-1,705,000 | $-1,708,000 |
| Change In Account Payable | $-1,705,000 | $-1,708,000 |
| Change In Prepaid Assets | $1,328,000 | $-8,176,000 |
| Change In Receivables | $-1,400,000 | $14,216,000 |
| Other Non Cash Items | $-15,564,000 | $9,309,000 |
| Stock Based Compensation | $19,148,000 | $8,664,000 |
| Amortization Of Securities | $-1,607,000 | $-23,000 |
| Depreciation Amortization Depletion | $1,006,000 | $525,000 |
| Depreciation And Amortization | $1,006,000 | $525,000 |
| Depreciation | $1,006,000 | $525,000 |
| Net Foreign Currency Exchange Gain Loss | $127,000 | $87,000 |
| Net Income From Continuing Operations | $-110,290,000 | $-196,300,000 |
| Issuance Of Debt | - | $0 |
| Net Issuance Payments Of Debt | - | $0 |
| Net Long Term Debt Issuance | - | $0 |
| Long Term Debt Issuance | - | $0 |
Fetched: 2026-02-02